Issue link: https://www.ascpskindeepdigital.com/i/581665
ascp and you: news notes Create your free business website! www.ascpskincare.com 45 High-Tech Beauty Living in Digital Times and the Consumer Electronics Association announced the launch of Beauty Tech, a special two-day series of showcases and panel discussions focused on technology for the beauty industry at the 2016 Consumer Electronics Show. The annual show will be held January 6–9 in Las Vegas. The latest tech advancements shaping the future of the industry will be on display, and are sure to be hot topics of discussion on the show floor. Attendees can expect to see and experience an array of digital innovations designed to help people look and feel their best, including augmented and virtual reality beauty experiences, and tools for skin, hair, and age-detection analysis. Attendees will also have access to professional advice from tech beauty experts. For more information, visit www.cesweb.org. Opportunities Abound Good news for job seekers! Spa Opportunities magazine reports an increase in the number of spa vacancies available, indicating that the spa market is continuing to bounce back from the global recession. "Our year-on-year monitoring shows a strong uplift in the volume of job opportunities available for professionals across the spa market, from director and management roles, through to therapist positions," says Spa Opportunities associate publisher Helen Andrews. Andrews also reports that the types of roles available are broadening, with more companies offering flexible employment terms. Find job listings across the United States and Europe at www.spaopportunities.com. A New Hope The FDA recently approved a drug for the treatment of locally advanced basal cell carcinoma (BCC), a common form of skin cancer. Taken in the form of a daily pill, Odomzo (generic name sonidegib) is marketed by Novartis AG, a Swiss pharmaceutical giant with headquarters in the United States. The US Food and Drug Administration says a trial showed the drug reduced or wiped out tumors in 58 percent of patients treated. Regulators note the drug is intended for patients with locally advanced basal cell carcinomas who are not candidates for surgery or radiotherapy, or whose tumors have recurred following such treatment. BCCs arise in basal cells in the epidermis, usually in places that receive regular sun exposure or other forms of ultraviolet radiation. They occur most frequently on the head and neck, with the nose being the most common specific site. The National Cancer Institute suggests the number of Americans diagnosed with nonmelanoma skin cancers is increasing every year. Read more about Odomzo here: www.fda.gov/newsevents/newsroom/ pressannouncements/ucm455862.htm.